Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06206915 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I Study of XZ120 in Malignant Tumors

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 16, 2024 (before its estimated February 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This research includes two parts: the first part of the patients with late malignant tumor monotherapy study, at the beginning of the second part in treat DLBCL and research on combination therapy in patients with advanced breast cancer. Research purpose: to evaluate XZ120 safety, tolerability, for the treatment of malignant tumor patients pharmacokinetic characteristics and preliminary effectiveness.
Trial Details
NCT Number NCT06206915
Lead Sponsor Shandong New Time Pharmaceutical Co., LTD
Collaborators: Fudan University, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions
(from sponsor)		 Advanced Malignancies
Enrollment 123 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov